Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Ah Ram | - |
dc.contributor.author | Park, Won | - |
dc.date.accessioned | 2021-09-10T05:24:15Z | - |
dc.date.available | 2021-09-10T05:24:15Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 2234-1900 | - |
dc.identifier.issn | 2234-3156 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18641 | - |
dc.description.abstract | Purpose: The purpose of this study was to describe treatment patterns of radiotherapy (RT) for prostate cancer in Korea. Materials and Methods: A questionnaire about radiation treatment technique and principles in 2013 was sent to 83 radiation oncologists and data from 57 hospitals were collected analyzed to find patterns of RT for prostate cancer patients in Korea. Results: The number of patients with prostate cancer treated with definitive RT ranged from 1 to 72 per hospital in 2013. RT doses and target volumes increased according to risk groups but the range of radiation doses was wide (60 to 81.4 Gy) and the fraction size was diverse (1.8 to 5 Gy). Intensity-modulated radiation therapy was used for definitive treatment in 93.8% of hospitals. Hormonal therapy was integrated with radiation for intermediate (63.2%) and high risk patients (77.2%). Adjuvant RT after radical prostatectomy was performed in 46 hospitals (80.7%). Indications of adjuvant RT included positive resection margin, seminal vesicle invasion, and capsular invasion. The total dose for adjuvant RT ranged from 50 to 72 Gy in 24-39 fractions. Salvage RT was delivered with findings of consecutive elevations in prostate-specific antigen (PSA), PSA level over 0.2 ng/mL, or clinical recurrence. The total radiation doses ranged from 50 to 80 Gy with a range of 1.8 to 2.5 Gy per fraction for salvage RT. Conclusion: This nationwide patterns of care study suggests that variable radiation techniques and a diverse range of dose fractionation schemes are applied for prostate cancer treatment in Korea. Standard guidelines for RT in prostate cancer need to be developed. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society for Therapeutic Radiology and Oncology | - |
dc.title | Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3857/roj.2016.01984 | - |
dc.identifier.scopusid | 2-s2.0-85017200262 | - |
dc.identifier.wosid | 000398899400003 | - |
dc.identifier.bibliographicCitation | Radiation Oncology Journal, v.35, no.1, pp 25 - 31 | - |
dc.citation.title | Radiation Oncology Journal | - |
dc.citation.volume | 35 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 25 | - |
dc.citation.endPage | 31 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002209991 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CONFORMAL RADIATION-THERAPY | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | ANDROGEN DEPRIVATION | - |
dc.subject.keywordPlus | SUPPRESSION | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | NEOADJUVANT | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | DURATION | - |
dc.subject.keywordPlus | ADJUVANT | - |
dc.subject.keywordAuthor | Prostate cancer | - |
dc.subject.keywordAuthor | Radiotherapy | - |
dc.subject.keywordAuthor | Patterns of care | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.